International Congress on Targeted Therapies in Cancer 2009

The Eighth International Congress on Targeted Therapies in Cancer has been designed to provide participants with cutting-edge information on novel targeted anticancer therapies now being developed, highlighting the mechanisms of action of and the most current clinical data on those agents. The congress will detail the multiple signaling pathways that are disrupted in cancer as well as novel targeted approaches that specifically affect aberrant signaling in tumor cells, such as the mTOR pathway; agents targeting the tumor microenvironment, including vascular-disrupting agents and angiopoietin as well as VEGF inhibitors; agents targeting molecules involved in developmental pathways; and agents that harness the body’s own immune system to combat neoplastic disease. Clinical applications of novel imaging techniques will be discussed. The congress will also cover novel therapeutic and drug discovery platforms and will explore efforts to use combinatorial approaches to fine-tune the effectiveness of monoclonal antibodies. Furthermore, a preview of new agents on the horizon for specific tumor types will be presented.

As the burgeoning field of targeted therapies continues to evolve, there is a clear need for physicians to be continuously updated on the most recent efficacy and safety data on these new classes of agents. The congress will use didactic learning and panel discussions to provide an educational program that allows physicians to keep abreast of these rapid developments.